Real-Life Use of Biosimilars in Pediatric Inflammatory Bowel Disease: A Nation-Wide Web Survey on Behalf of the SIGENP IBD Working Group.
Journal
Paediatric drugs
ISSN: 1179-2019
Titre abrégé: Paediatr Drugs
Pays: Switzerland
ID NLM: 100883685
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
accepted:
30
11
2021
pubmed:
17
12
2021
medline:
11
1
2022
entrez:
16
12
2021
Statut:
ppublish
Résumé
The aim was to assess the awareness and real-life use of biosimilars in inflammatory bowel disease (IBD) among the members of the Italian Society of Pediatric Gastroenterology, Hepatology and Nutrition (SIGENP). An anonymous web survey involving all SIGENP IBD units which can prescribe biosimilars was conducted between July 1st and December 1st, 2020. The questionnaire included 18 questions addressing the most relevant aspects of biosimilars in pediatric IBD, i.e., advantages, disadvantages, costs, traceability, general knowledge, and real-life use. A descriptive analysis of responses was performed. Responses came from 26 pediatric IBD units in Italy, with representation of the North, the Center, and the South of Italy. The majority of participants (n = 20) had spent > 10 years caring for pediatric IBD patients, and worked in a center which had between 100 and 500 registered pediatric IBD patients (n = 14). Most participants (n = 18) reported they were aware that biosimilars have similar efficacy and safety to those of the originator, and all regarded cost-sparing as the main advantage of biosimilars. Most respondents (n = 20) reported they switch from originator to biosimilar in their everyday clinical practice, mostly during the maintenance phase. Most respondents (n = 20) registered no acute adverse events. Nearly all participants felt totally or very confident in using biosimilars. A few years after the introduction of the first biosimilar into the market, real-life data coming from the major IBD units in Italy confirm a favorable and confident position on the use of biosimilars in pediatric IBD.
Identifiants
pubmed: 34914084
doi: 10.1007/s40272-021-00486-8
pii: 10.1007/s40272-021-00486-8
doi:
Substances chimiques
Biosimilar Pharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
57-62Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Danese S, Fiorino G, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn’s and Colitis Organization. J Crohns Colitis. 2014;8:1548–50.
doi: 10.1016/j.crohns.2014.06.007
Danese S, Fiorino G, Michetti P. Changes in biosimilar knowledge among European Crohn’s Colitis Organization [ECCO] Members: an updated survey. J Crohns Colitis. 2016;10:1362–5.
doi: 10.1093/ecco-jcc/jjw090
de Ridder L, Assa A, Bronsky J, et al. Use of biosimilars in pediatric inflammatory bowel disease: an updated position statement of the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2019;68:144–53.
doi: 10.1097/MPG.0000000000002141
Dipasquale V, Romano C. Biosimilar infliximab in paediatric inflammatory bowel disease: Efficacy, immunogenicity and safety. J Clin Pharm Ther. 2020;45:1228–34.
doi: 10.1111/jcpt.13239
Park SK, Moon W, Kim ES, et al. Knowledge and viewpoints on biosimilar monoclonal antibodies among Asian physicians: comparison with European physicians. Korean J Gastroenterol. 2019;74:333–40.
doi: 10.4166/kjg.2019.74.6.333
Danese S, Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7:586–9.
doi: 10.1016/j.crohns.2013.03.011
Fiorino G, Girolomoni G, Lapadula G, et al. The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev. 2014;13:751–5.
doi: 10.1016/j.autrev.2014.02.004
Annese V, Vecchi M. Use of biosimilars in inflammatory bowel disease: statements of the Italian Group for Inflammatory Bowel Disease. Dig Liver Dis. 2014;46:963–8.
doi: 10.1016/j.dld.2014.07.019
Raffaelli EA, Massimino F. Biosimilars: considerations in light of the Italian legal framework. Generics Biosimilars Initiative J (GaBI Journal). 2019;8:5–23.
doi: 10.5639/gabij.2019.0801.002
Sieczkowska J, Jarzębicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis. 2016;10:127–32.
doi: 10.1093/ecco-jcc/jjv233
Gervais L, McLean LL, Wilson ML, et al. Switching from originator to biosimilar infliximab in paediatric inflammatory bowel disease is feasible and uneventful. J Pediatr Gastroenterol Nutr. 2018;67:745–8.
doi: 10.1097/MPG.0000000000002091
van Hoeve K, Dreesen E, Hoffman I, et al. Efficacy, pharmacokinetics, and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease. Ther Drug Monit. 2019;41:317–24.
doi: 10.1097/FTD.0000000000000601
Kang B, Lee Y, Lee K, et al. Long-term outcomes after switching to CT-P13 in pediatric-onset inflammatory bowel disease: a single-center prospective observational study. Inflamm Bowel Dis. 2018;24:607–16.
doi: 10.1093/ibd/izx047
Richmond L, Curtis L, Garrick V, et al. Biosimilar infliximab use in paediatric IBD. Arch Dis Child. 2018;103:89–91.
doi: 10.1136/archdischild-2017-313404